Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II exploratory trial of JYP0061 in acute neuromyelitis optica spectrum disorder
CTR20231449Phase 2Active
- Sponsor
- Guangzhou JOYO Pharma
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JYP0061 in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Guangzhou JOYO Pharma. Started May 2023; status: active.
02
Drugs
JYP0061
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20231449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231449.